Calebin A Inhibits Adipogenesis and Leptin Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current obesity management strategies lack a safe and effective natural approach to inhibit adipogenesis and modulate biochemical markers associated with obesity, such as leptin production, adiponectin expression, and inflammation caused by pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β.
Innovation Solution
Calebin A is used to inhibit adipogenesis, reduce leptin production, increase adiponectin expression, and decrease the expression of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β, thereby preventing fat accumulation and managing obesity by contacting adipocytes with an effective amount of Calebin A.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs are used to treat obesity, then weight reduction may be achieved, but safety concerns and side effects arise
Solution Approach 1:
The patent uses a naturally occurring compound (calebin A) from Plantago major instead of synthetic pharmaceuticals. This natural compound provides the therapeutic effect with improved safety profile, replacing long-term use of potentially harmful synthetic drugs with a safer natural alternative that can be administered as needed.
Solution Approach 2:
Calebin A acts as an intermediary natural compound that mediates between the desired weight reduction effect and safety concerns. It provides the therapeutic action through natural biochemical pathways, reducing harmful side effects while maintaining efficacy in treating obesity and related metabolic disorders.
2Reliability
If adipogenesis is stimulated to treat diabetes, then blood sugar control improves, but fat accumulation and obesity increase
Solution Approach 1:
The patent applies local quality by selectively modulating adipogenesis in specific contexts. Calebin A promotes adipocyte differentiation and glucose uptake in diabetic conditions where this is beneficial, while simultaneously inhibiting excessive fat accumulation through regulation of lipid metabolism pathways, achieving different outcomes in different metabolic contexts.
Solution Approach 2:
Calebin A changes the parameters of adipocyte function by enhancing glucose uptake and insulin sensitivity while regulating lipid storage capacity. This allows the body to utilize adipose tissue more effectively for glucose disposal without necessarily increasing overall fat mass, thereby improving blood sugar control without proportionally increasing obesity risk.
Data Source
AI summary
The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-α), Interleukin-6 (IL-6) and Interleukin-1 (IL-1β).